Journal of Medicinal Chemistry · 2004 · 22 citations · 12 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryNeuropharmacologyStructure-activity RelationshipsDrug-receptor InteractionsLigand BindingLigand-based DesignReceptor PharmacologyReceptor-ligand InteractionsStructure-activity Relationship AnalysisAffinity LigandsAgonist ActivityD2-like Dopamine ReceptorsDopamine D1-like ReceptorsDopamine D2-like ReceptorsLigand Design For ReceptorsPiperidine ChemistryStructure-based Ligand Design
In the attempt to define more accurately structure-affinity relationships for sigma(1) and sigma(2) ligands, we synthesized and tested on sigma subtype receptors a series of aralkyl derivatives of 4-benzylpiperidine, in which the effect of modifications on the aralkyl moiety was studied in a systematic way. The affinity of the compounds here described varied to a great extent, with a sigma(2)/sigma(1) selectivity ranging from 0.1 to 9. Thus, to confirm the ability of the piperazine derivative to bind to sigma(1) receptors in a different way than piperidines, we synthesized and tested a series of piperazine compounds; the comparison of their affinity with that of the corresponding piperidines strongly supports the possibility of a different binding mode. While the compounds here described are on the whole selective for sigma vs serotonin 5-HT(1A) and dopamine D(2) receptors, 9aa, 9ba and 9ab possess a remarkable affinity for both sigma and 5-HT(1A) receptors, with K(i) in the nanomolar range, and are selective with respect to D(2) receptors. They displayed also a partial agonist profile in a human 5-HT(1A) [(35)S]GTP gamma S binding assay, suggesting their potential use as atypical antipsychotic agents.
12
Binding of antipsychotic drugs to human brain receptors
Elliott Richelson, Terry Souder · Life Sciences · 2000 · 598 citations · Full text
Medicine, Pharmacology, Psychiatry +13
Karen E. Linder, Yee Wai Chan, John E. Cyr et al. · Journal of Medicinal Chemistry · 1994 · 120 citations